Skip to main content
SpringerLink
Log in
Book cover

Pulmonary Hypertension pp 283–303Cite as

Endothelin and Its Blockade in Pulmonary Arterial Hypertension

  • Chapter

  • 1559 Accesses

Part of the book series: Contemporary Cardiology™ ((CONCARD))

Abstract

Endothelin-1, a potent vasoconstrictor and mitogenic peptide manufactured by endothelial cells, has been identified as an important mediator in human pulmonary arterial hypertension. Endothelin-1 binds to two different receptors, termed ETA and ETB. While it is generally agreed that the ETA receptor is the predominant receptor responsible for constriction and proliferation, it is unclear whether the net effect of ETB-receptor activation is beneficial or detrimental. In the past decade, the development of both nonspecific and specific ETA endothelin-receptor antagonists has offered hope of benefit for patients with PAH. These agents have the advantage of permitting oral administration with once- or twice-daily dosing. They improve functional status and capacity as well as pulmonary hemodynamics and slow the time to clinical worsening. Elevation of liver enzymes appears to be a class effect, although some agents may be less liver-toxic than others. However, many questions remain to be answered about the role of endothelin and its receptors in the pathogenesis and therapy of PAH.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411–5.

    Article  PubMed  CAS  Google Scholar 

  2. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med 1991; 114:464–9.

    PubMed  CAS  Google Scholar 

  3. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy RD, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732–9.

    Article  PubMed  CAS  Google Scholar 

  4. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348:730–2.

    Article  PubMed  CAS  Google Scholar 

  5. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348:732–4.

    Article  PubMed  CAS  Google Scholar 

  6. Sham JK, Crenshaw BR, Deng LH, Shimoda LA, Sylvester JT. Effects of hypoxia in porcine pulmonary arterial myocytes: Role of Kv channel and endothelin-1. Am J Physiol (Lung Cell Mol Physiol) 2000; 279: L262–L272.

    CAS  Google Scholar 

  7. Kawanabe Y, Okamoto Y, Nozaki K, Hashimoto N, Miwa S, Masaki T. Molecular mechanisms for endothelin-1-induced stress fiber formation: Analysis of G proteins using a mutant endothelin (A) receptor. Mol Pharmacol 2002; 61:277–84.

    Article  PubMed  CAS  Google Scholar 

  8. Kedzierski RM, Yanagisawa M. Endothelin system: The double-edged sword in health and disease. Ann Rev Pharmacol Toxicol 2001; 41:851–76.

    Article  CAS  Google Scholar 

  9. Iwamuro Y, Miwa S, Zhang XF, Minowa T, Enoki T, Okamoto Y, et al. Activation of three types of voltage-independent Ca$2+$ channel in A7r5 cells by endothelin-1 as revealed by a novel Ca$2+$ channel blocker LOE 908. Br J Pharmacol 1999; 126:1107–14.

    Article  PubMed  CAS  Google Scholar 

  10. Evans AM, Cobban HJ, Nixon GF. ET$_A$ receptors are the primary mediators of myofilament calcium sensitization induced by ET-1 in rat pulmonary artery smooth muscle: A tyrosine kinase independent pathway. Br J Pharmacol 1999; 127:153–60.

    Article  PubMed  CAS  Google Scholar 

  11. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW. ET$_A$ and ET$_B$ receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165:398–405.

    PubMed  Google Scholar 

  12. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004; 15:2707–19.

    Article  PubMed  Google Scholar 

  13. Muramatsu M, Rodman DM, Oka M, McMurtry IF. Endothelin-1 mediates nitro-L-arginine vasoconstriction of hypertensive rat lungs. Am J Physiol (Lung Cell Mol Physiol) 1997; 272:L807–L812.

    CAS  Google Scholar 

  14. Black SM, Mata-Greenwood E, Dettman RW, Ovadia B, Fitzgerald RK, Reinhartz O, et al. Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation 2003; 108: 1646–54.

    Article  PubMed  CAS  Google Scholar 

  15. De Nucci G, Thomas R, D’Orleans-Juste P, Antunes E, Walder C, Warner TD, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988; 85:9797–800.

    Article  PubMed  Google Scholar 

  16. Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996; 94:1578–84.

    PubMed  CAS  Google Scholar 

  17. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ETB receptors. J Appl Physiol 1996; 81:1510–5.

    PubMed  CAS  Google Scholar 

  18. Dupuis J, Goresky CA, Stewart DJ. Pulmonary removal and production of endothelin in the anesthetized dog. J Appl Physiol 1994; 76:694–700.

    PubMed  CAS  Google Scholar 

  19. Langleben D, Dupuis J, Langleben I, Hirsch AM, Baron M, Senecal JL, et al. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest 2006; 129:689–95.

    Article  PubMed  Google Scholar 

  20. Adner M, Geary GG, Edvinsson L. Appearance of contractile endothelin-B receptors in rat mesenteric arterial segments following organ culture. Acta Physiol Scand 1998; 163:121–9.

    Article  PubMed  CAS  Google Scholar 

  21. Muramatsu M, Oka M, Morio Y, Soma S, Takahashi H, Fukuchi Y. Chronic hypoxia augments endothelin-B receptor-mediated vasodilation in isolated perfused rat lungs. Am J Physiol (Lung Cell Mol Physiol) 1999; 276:L358–L364.

    CAS  Google Scholar 

  22. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Shi-Wen X, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997; 151:831–41.

    PubMed  CAS  Google Scholar 

  23. Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H, Schafers HJ. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002; 105:1034–6.

    Google Scholar 

  24. Clozel M, Loffler BM, Breu V, Hilfiger L, Maire JP, Butscha B. Downregulation of endothelin receptors by autocrine production of endothelin-1. Am J Physiol (Cell Physiol) 1993; 265:C188–C192.

    CAS  Google Scholar 

  25. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001; 69:223–31.

    Article  PubMed  CAS  Google Scholar 

  26. Williamson DJ, Wallman LL, Jones R, Keogh AM, Scroope F, Penny R, et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000; 102:411–8.

    PubMed  CAS  Google Scholar 

  27. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001; 358:1119–23.

    Article  PubMed  CAS  Google Scholar 

  28. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896–903.

    Article  PubMed  CAS  Google Scholar 

  29. Galie N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41:1380–6.

    Article  PubMed  Google Scholar 

  30. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension. Chest 2003; 124:247–54.

    Article  PubMed  CAS  Google Scholar 

  31. McLaughlin V, Sitbon O, Rubin LJ, Levy P, Barst R, Badesch D, et al. The effect of first-line bosentan on survival of patients with primary pulmonary hypertension. Am J Resp Crit Care Med 2003; 167:A442.

    Google Scholar 

  32. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002; 106:1477–82.

    Article  PubMed  CAS  Google Scholar 

  33. Kim NH, Channick RN, Rubin LJ. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest 2003; 124:1612–5.

    Article  PubMed  Google Scholar 

  34. Ivy DD, Doran A, Claussen L, Bingaman D, Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 2004; 93:943–6.

    Article  PubMed  CAS  Google Scholar 

  35. Suleman N, Frost AE. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest 2004; 126:808–15.

    Article  PubMed  CAS  Google Scholar 

  36. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22:330–4.

    Article  PubMed  CAS  Google Scholar 

  37. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24:353–9.

    Article  PubMed  CAS  Google Scholar 

  38. Barst RJ, Dunbar I, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73:372–82.

    Article  PubMed  CAS  Google Scholar 

  39. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170:1212–7.

    Article  PubMed  Google Scholar 

  40. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114:48–54.

    Article  PubMed  Google Scholar 

  41. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: Open-label pilot study. Chest 2002 Jun; 121(6):1860–8.

    Google Scholar 

  42. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz RJ, Shapiro SM, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169:441–7.

    Article  PubMed  Google Scholar 

  43. Langleben D, Hirsch AM, Shalit E, Lesenko L, Barst RJ. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension. Chest 2004; 126:1377–81.

    Article  PubMed  CAS  Google Scholar 

  44. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47:2049–56.

    Google Scholar 

  45. Benza R, Frost A, Girgis R, Langleben D, Lawrence EC, Naeije R. Chronic treatment of pulmonary arterial hypertension with sitaxsentan and bosentan. Proc Am Thorac Soc 2006; 3:A729.

    Google Scholar 

  46. Pulido T, Kurzyna M, Souza R, Ramirez A, Sandoval J. Sitaxsentan 100 mg proves more effective than sitaxsentan 50 mg in patients with pulmonary arterial hypertension. Proc Am Thorac Soc 2006; 3:A417.

    Google Scholar 

  47. Benza R, Mehta S, Keogh A, Lawrence EC, Oudiz R, Barst RJ. Sitaxsentan treatment for patients with pulmonary arterial hypertension failing bosentan treatment. Proc Am Thorac Soc 2005; 2:A201.

    Google Scholar 

  48. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005 Aug 2; 46(3):529–35.

    Google Scholar 

  49. ARIES-1 News Release, April 10, 2006.

    Google Scholar 

  50. Olschewski H, Galie N, Ghofrani HA, Kramer MR, Rubin LJ. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: Results of the ARIES-2 study. Proc Am Thorac Soc 2006; 3:A728.

    Google Scholar 

  51. Langleben D, Brock T, Dixon R, Barst R. STRIDE-1: Effects of the selective ET-A receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. J Cardiovasc Pharmacol 2004; 44:S80–S84.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. David Langleben
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Pulmonary, Critical Care and Sleep Medicine Tufts Medical Center, Boston, MA

    Nicholas S. Hill MD

  2. Pulmonary Center, Boston University, Boston, MA

    Harrison W. Farber MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, Totowa, NJ

About this chapter

Cite this chapter

Langleben, D. (2008). Endothelin and Its Blockade in Pulmonary Arterial Hypertension. In: Hill, N.S., Farber, H.W. (eds) Pulmonary Hypertension. Contemporary Cardiology™. Humana Press. https://doi.org/10.1007/978-1-60327-075-5_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-075-5_13

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-661-0

  • Online ISBN: 978-1-60327-075-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation